Cash for NOX

Genkyotex S.A.'s CHF25 million ($26.3 million) series C round extension may be the last financing the biotech needs if everything goes to plan. The cash will get the company's lead program through Phase II testing in diabetic nephropathy and, potentially, to an exit.

The extension, which the company was expected to announce on Monday this week, will bring the total for the series C round to CHF43 million ($46.7 million). Existing investors Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, and MP Healthcare Venture are participating...